Role of perioperative magnesium sulfate to control blood sugar in patients with diabetes undergoing cardiac surgery on cardiopulmonary bypass

The effect of perioperative magnesium sulfate on blood sugar in patients with diabetes mellitus undergoing cardiac surgery on cardiopulmonary bypass: A double blinded randomized study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072536

Enrollment

100

Registered

2024-08-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: DRUG GIVEN: GIVING PERIOPERATIVE MAGNESIUM SULFATE Intervention2: Perioperative Magnesium Sulfate infusion: Continous intravenous infusion of Magnesium Sulfate at 15mg/kg/hr. Infusion w

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients with diabetes mellitus Ejection fraction more than 40 percent

Exclusion criteria

Exclusion criteria: congestive heart failure acute myocardial infarction emergency cardiac surgery redo cases cardiomyopathies heart rate less than 50 bpm pericardial disease renal / hepatic impairment.

Design outcomes

Primary

Measure	Time frame
measure the efficacy of magnesium infusion in reducing the blood glucose levelsTimepoint: blood levels of magnesium, sugar, and potassium T0 Baseline reading (before starting the administration of study medication) T1 Reading before CPB T2 Reading after CPB T3 Reading 6 hr after ICU admission T4 reading 12 hr after ICU admission T5 Reading 24 hr after ICU admission	—

Secondary

Measure	Time frame
requirement for insulin infusion in addition to the safety of the study medication, which is assessed by the occurrence of any adverse eventsTimepoint: Requirement of insulin (total units & units/hr) in first 24 hrs urine output per hour in 1st 24 hrs pharmacological & mechanical support need till 4 weeks Major Adverse Cardiac Event/ Arrythmia till 4 weeks Organ Dysfunction till 4 weeks Mortality in 4 weeks	—

Measure

Time frame

requirement for insulin infusion in addition to the safety of the study medication, which is assessed by the occurrence of any adverse eventsTimepoint: Requirement of insulin (total units & units/hr) in first 24 hrs urine output per hour in 1st 24 hrs pharmacological & mechanical support need till 4 weeks Major Adverse Cardiac Event/ Arrythmia till 4 weeks Organ Dysfunction till 4 weeks Mortality in 4 weeks

—

Countries

India

Contacts

Public ContactMadhuri Priyadarshi

LPS Institute Of Cardiology, GSVM Medical College

priyadarshi.madhuri@gmail.com9415211145

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026